Literature DB >> 19515624

Invasive candidiasis: an overview from Taiwan.

Sheng-Yuan Ruan1, Po-Ren Hsueh.   

Abstract

Invasive candidiasis has emerged as an important nosocomial infection, especially in critically ill patients. We review the epidemiology of invasive candidiasis with an emphasis on data from Taiwan. An increasing incidence of candidemia became apparent from 1980 to the end of the 1990s, followed by relative stability. Crude mortality rates of patients with candidemia were in the range of 35% to 60%. Candida albicans remains the predominant cause of invasive candidiasis in Taiwan and accounts for more than 50% of all cases. Candida tropicalis, Candida glabrata and Candida parapsilosis are the three most common non-albicans Candida species that cause invasive candidiasis. The above four Candida species account for more than 90% of invasive candidiasis in Taiwan. Overall, invasive Candida isolates have remained highly susceptible to fluconazole (> 90% susceptibility) over the past two decades. However, periodic surveillance is needed to monitor antifungal resistance because reduced fluconazole susceptibility in non-albicans Candida is not an uncommon trend. Voriconazole and echinocandins continue to exhibit excellent in vitro activity against invasive Candida isolates.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19515624     DOI: 10.1016/S0929-6646(09)60091-7

Source DB:  PubMed          Journal:  J Formos Med Assoc        ISSN: 0929-6646            Impact factor:   3.282


  16 in total

1.  Waikialoid A suppresses hyphal morphogenesis and inhibits biofilm development in pathogenic Candida albicans.

Authors:  Xiaoru Wang; Jianlan You; Jarrod B King; Douglas R Powell; Robert H Cichewicz
Journal:  J Nat Prod       Date:  2012-03-08       Impact factor: 4.050

2.  Antifungal susceptibilities of Candida isolates causing bloodstream infections at a medical center in Taiwan, 2009-2010.

Authors:  Yu-Tsung Huang; Chia-Ying Liu; Chun-Hsing Liao; Kuei-Pin Chung; Wang-Huei Sheng; Po-Ren Hsueh
Journal:  Antimicrob Agents Chemother       Date:  2014-04-21       Impact factor: 5.191

3.  Time to positivity of blood culture can predict different Candida species instead of pathogen concentration in candidemia.

Authors:  L Huang; Y Y Zhang; L Y Sun
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-02-01       Impact factor: 3.267

4.  Small-molecule suppressors of Candida albicans biofilm formation synergistically enhance the antifungal activity of amphotericin B against clinical Candida isolates.

Authors:  Jianlan You; Lin Du; Jarrod B King; Brian E Hall; Robert H Cichewicz
Journal:  ACS Chem Biol       Date:  2013-02-14       Impact factor: 5.100

5.  Historical trends in the epidemiology of candidaemia: analysis of an 11-year period in a tertiary care hospital in Brazil.

Authors:  Marcos Paulo Wille; Thaís Guimarães; Guilherme Henrique Campos Furtado; Arnaldo Lopes Colombo
Journal:  Mem Inst Oswaldo Cruz       Date:  2013-05       Impact factor: 2.743

Review 6.  Candida glabrata: a review of its features and resistance.

Authors:  C F Rodrigues; S Silva; M Henriques
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-11-19       Impact factor: 3.267

7.  Heat stable antimicrobial activity of Burkholderia gladioli OR1 against clinical drug resistant isolates.

Authors:  Pratibha Bharti; Vivek Anand; Jagdish Chander; Inder Pal Singh; Tej Vir Singh; Rupinder Tewari
Journal:  Indian J Med Res       Date:  2012-05       Impact factor: 2.375

8.  High Incidences of Invasive Fungal Infections in Acute Myeloid Leukemia Patients Receiving Induction Chemotherapy without Systemic Antifungal Prophylaxis: A Prospective Observational Study in Taiwan.

Authors:  Jih-Luh Tang; Hsiang-Chi Kung; Weng-Chi Lei; Ming Yao; Un-In Wu; Szu-Chun Hsu; Chien-Ting Lin; Chi-Cheng Li; Shang-Ju Wu; Hsin-An Hou; Wen-Chien Chou; Shang-Yi Huang; Woei Tsay; Yao-Chang Chen; Yee-Chun Chen; Shan-Chwen Chang; Bor-Sheng Ko; Hwei-Fang Tien
Journal:  PLoS One       Date:  2015-06-10       Impact factor: 3.240

9.  Intravenous anidulafungin followed optionally by oral voriconazole for the treatment of candidemia in Asian patients: results from an open-label Phase III trial.

Authors:  Piroon Mootsikapun; Po-Ren Hsueh; Deepak Talwar; Vilma M Co; Viraj Rajadhyaksha; Moh-Lim Ong
Journal:  BMC Infect Dis       Date:  2013-05-15       Impact factor: 3.090

10.  Systemic Candida parapsilosis Infection Model in Immunosuppressed ICR Mice and Assessing the Antifungal Efficiency of Fluconazole.

Authors:  Yu'e Wu; Fangui Min; Jinchun Pan; Jing Wang; Wen Yuan; Yu Zhang; Ren Huang; Lixin Zhang
Journal:  Vet Med Int       Date:  2015-07-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.